1h Free Analyst Time
The publisher has been monitoring the small molecule API market and it is poised to grow by $71.10 bn during 2022-2026, progressing at a CAGR of 7.89% during the forecast period. The report on the small molecule API market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by evolving small-molecule API manufacturing scenario in developing countries and the increasing number of type II drug master files.
The small molecule API market analysis includes the deployment segment and geographic landscape.
The small molecule API market is segmented as below:
By Deployment
- Captive APIs
- Contract APIs
By Geographical Landscape
- North America
- Asia
- Europe
- ROW
This study identifies the growing need to focus on core competencies as one of the prime reasons driving the small molecule API market growth during the next few years.
The report on small molecule API market covers the following areas:
- Small molecule API market sizing
- Small molecule API market forecast
- Small molecule API market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading small molecule API market vendors that include Aurobindo Pharma Ltd., Cambrex Corp., Cipla Inc., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the small molecule API market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2021
- Market outlook: Forecast for 2021 - 2026
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Deployment
- Market segments
- Comparison by Deployment
- Captive APIs - Market size and forecast 2021-2026
- Contract APIs - Market size and forecast 2021-2026
- Market opportunity by Deployment
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2021-2026
- Asia - Market size and forecast 2021-2026
- Europe - Market size and forecast 2021-2026
- ROW - Market size and forecast 2021-2026
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Aurobindo Pharma Ltd.
- Cambrex Corp.
- Cipla Inc.
- Dr. Reddys Laboratories Ltd.
- GlaxoSmithKline Plc
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2021 - 2026 ($ billion)
- Global market: Year-over-year growth 2021 - 2026 (%)
- Five forces analysis 2021 & 2026
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2021
- Deployment - Market share 2021-2026 (%)
- Comparison by Deployment
- Captive APIs - Market size and forecast 2021-2026 ($ billion)
- Captive APIs - Year-over-year growth 2021-2026 (%)
- Contract APIs - Market size and forecast 2021-2026 ($ billion)
- Contract APIs - Year-over-year growth 2021-2026 (%)
- Market opportunity by Deployment
- Customer landscape
- Market share By Geographical Landscape 2021-2026 (%)
- Geographic comparison
- North America - Market size and forecast 2021-2026 ($ billion)
- North America - Year-over-year growth 2021-2026 (%)
- Asia - Market size and forecast 2021-2026 ($ billion)
- Asia - Year-over-year growth 2021-2026 (%)
- Europe - Market size and forecast 2021-2026 ($ billion)
- Europe - Year-over-year growth 2021-2026 (%)
- ROW - Market size and forecast 2021-2026 ($ billion)
- ROW - Year-over-year growth 2021-2026 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ billion)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- Aurobindo Pharma Ltd. - Overview
- Aurobindo Pharma Ltd. - Product and service
- Aurobindo Pharma Ltd. - Key offerings
- Aurobindo Pharma Ltd. - Key customers
- Aurobindo Pharma Ltd. - Segment focus
- Cambrex Corp. - Overview
- Cambrex Corp. - Product and service
- Cambrex Corp. - Key offerings
- Cambrex Corp. - Key customers
- Cambrex Corp. - Segment focus
- Cipla Inc. - Overview
- Cipla Inc. - Business segments
- Cipla Inc. - Key offerings
- Cipla Inc. - Key customers
- Cipla Inc. - Segment focus
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Key customers
- Dr. Reddys Laboratories Ltd. - Segment focus
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Key customers
- GlaxoSmithKline Plc - Segment focus
- Merck KGaA - Overview
- Merck KGaA - Business segments
- Merck KGaA - Key offerings
- Merck KGaA - Key customers
- Merck KGaA - Segment focus
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key offerings
- Novartis AG - Key customers
- Novartis AG - Segment focus
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Key customers
- Pfizer Inc. - Segment focus
- Teva Pharmaceutical Industries Ltd. - Overview
- Teva Pharmaceutical Industries Ltd. - Business segments
- Teva Pharmaceutical Industries Ltd. - Key offerings
- Teva Pharmaceutical Industries Ltd. - Key customers
- Teva Pharmaceutical Industries Ltd. - Segment focus
- Viatris Inc. - Overview
- Viatris Inc. - Business segments
- Viatris Inc. - Key offerings
- Viatris Inc. - Key customers
- Viatris Inc. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global small molecule API market: Aurobindo Pharma Ltd., Cambrex Corp., Cipla Inc., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is growing need to focus on core competencies.`
According to the report, one of the major drivers for this market is the evolving small-molecule API manufacturing scenario in developing countries.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurobindo Pharma Ltd.
- Cambrex Corp.
- Cipla Inc.
- Dr. Reddys Laboratories Ltd.
- GlaxoSmithKline Plc
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
